Lyra Therapeutics (LYRA) Cash from Financing Activities (2019 - 2025)
Quarterly Cash from Financing Activities fell 1500.0% to -$368000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$392000.0 through Dec 2025, down 104.6% year-over-year, with the annual reading at $4.3 million for FY2025, 49.91% down from the prior year.
Lyra Therapeutics' Cash from Financing Activities history spans 7 years, with the latest figure at -$368000.0 for Q3 2025.
- Cash from Financing Activities came in at -$368000.0 for Q3 2025, down from -$1000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $96.5 million in Q2 2022 to a low of -$418000.0 in Q3 2023.
- The 5-year median for Cash from Financing Activities is $1500.0 (2023), against an average of $10.7 million.
- Year-over-year, Cash from Financing Activities skyrocketed 216000.0% in 2024 and then crashed 1500.0% in 2025.
- Lyra Therapeutics' Cash from Financing Activities stood at -$4000.0 in 2021, then plummeted by 5800.0% to -$236000.0 in 2022, then skyrocketed by 8116.95% to $18.9 million in 2023, then tumbled by 100.01% to -$1000.0 in 2024, then plummeted by 36700.0% to -$368000.0 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Cash from Financing Activities are -$368000.0 (Q3 2025), -$1000.0 (Q4 2024), and -$23000.0 (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -802.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Lyra Therapeutics | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -368,000.00 |
| Sep 30, 2025 | -368,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -89,000.00 |
| Jun 30, 2024 | -89,000.00 |
| Mar 31, 2024 | 8.64 Mn |
| Mar 31, 2024 | 8.64 Mn |
| Dec 31, 2023 | 18.92 Mn |
| Dec 31, 2023 | 18.92 Mn |
| Sep 30, 2023 | -418,000.00 |
| Sep 30, 2023 | -418,000.00 |
| Jun 30, 2023 | 47.19 Mn |
| Jun 30, 2023 | 47.19 Mn |
| Mar 31, 2023 | 4,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Sep 30, 2022 | -236,000.00 |
| Sep 30, 2022 | -236,000.00 |
| Jun 30, 2022 | 96.49 Mn |
| Jun 30, 2022 | 96.49 Mn |
| Mar 31, 2022 | 6,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | -4,000.00 |
| Dec 31, 2021 | -4,000.00 |
| Sep 30, 2021 | -84,000.00 |
| Sep 30, 2021 | -84,000.00 |
| Jun 30, 2021 | 185,000.00 |
| Jun 30, 2021 | 185,000.00 |
| Mar 31, 2021 | 262,000.00 |
| Mar 31, 2021 | 262,000.00 |
| Dec 31, 2020 | 7,000.00 |
| Dec 31, 2020 | 7,000.00 |
| Sep 30, 2020 | -675,000.00 |
| Sep 30, 2020 | -675,000.00 |
| Jun 30, 2020 | 58.91 Mn |
| Jun 30, 2020 | 58.91 Mn |
| Mar 31, 2020 | 29.46 Mn |
| Mar 31, 2020 | 29.46 Mn |
| Dec 31, 2019 | -198,000.00 |
| Dec 31, 2019 | -198,000.00 |
| Sep 30, 2019 | -4,000.00 |
| Sep 30, 2019 | -4,000.00 |